Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat plus azacitidine in higher-risk MDS, CMML, and low-blast AML
NCT03268954Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of pevonedistat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Takeda. Primary endpoint: Event-Free Survival at 42 months. Started Nov 2017; status: completed.
02
Drugs
pevonedistat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03268954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268954.